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Recommended Immunization Schedules  
Each year, the Advisory Committee on Immunization Practices (ACIP) reviews the recommended 
immunization schedules for children, adolescents and adults. This schedule summarizes the 
recommendations for currently licensed vaccines in the United States. Changes to the 2011 
Childhood/Adolescent Immunization Schedules include the following: 
• Guidance has been added for the hepatitis B vaccine schedule for children who did   
not receive a birth dose. 
• Information on use of 13-valent pneumococcal conjugate vaccine has been added. 
• Guidance has been added for administration of 1 or 2 doses of seasonal influenza 
vaccine based upon the child's history of monovalent 2009 H1N1 vaccination. 
• Use of tetanus and diphtheria toxoids, and acellular pertussis (Tdap) vaccine among 
children aged 7 through 10 years who are incompletely vaccinated against pertussis is 
addressed, and reference to a specified interval between tetanus and diphtheria 
toxoids (Td) and Tdap vaccination has been removed.  
• Footnotes for the use of human papillomavirus (HPV) vaccine have been condensed. 
• Routine 2-dose schedule of quadrivalent meningococcal conjugate vaccine (MCV4) for 
certain persons at high risk for meningococcal disease, and recommendations for a 
booster dose of MCV4 have been added. 
• Guidance for use of Haemophilus influenzae type b (Hib) vaccine in persons aged 5 
years and older in the catch-up schedule has been condensed. 
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Changes to the 2011 Adult Immunization Schedule include the following: 
• The notation for influenza vaccination in the schedule and footnotes was changed to 
reflect the expanded recommendation for annual influenza vaccination for all persons 
aged 6 months and older.  
• In October 2010, ACIP issued a permissive recommendation for use of tetanus, 
diphtheria, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older, 
approved the recommendation that Tdap vaccine be administered regardless of how 
much time has elapsed since the most recent tetanus and diphtheria toxoids (Td)-
containing vaccine, and approved a recommendation for a 2-dose series of 
meningococcal vaccine in adults with certain high-risk medical conditions. 
• The vaccines listed in the schedule have been reordered to keep all universally 
recommended vaccines together (e.g., influenza, Td/Tdap, varicella, human 
papillomavirus [HPV], and zoster vaccines). 
• Clarifications were made to the footnotes for measles, mumps, and rubella (MMR) 
vaccination; HPV vaccine; revaccination with pneumococcal polysaccharide vaccine 
(PPSV), and Haemophilus influenza type b (Hib) vaccine. 
• A statement has been added to the box at the bottom of the footnotes to clarify that a 
vaccine series does not need to be restarted, regardless of the time that has elapsed 
between doses.  
Click on this link for several available formats: child, adolescent, and catch-up schedules  
The adult schedule is available in several formats at this link: adult immunization schedule 
 
Zoster Vaccine 
 
On March 24, 2011, the U.S. Food and Drug Administration (FDA) approved Merck's license supplement 
to expand the use of zoster vaccine to persons 50 through 59 years of age.  This approval was based on 
a large clinical trial that demonstrated the efficacy and safety of zoster vaccine in this age group. 
Vaccine providers may now administer zoster vaccine for persons 50 years and older who are not 
pregnant or immunosuppressed. 
 
The Advisory Committee on Immunization Practices (ACIP) Zoster Work Group has been discussing the 
use of zoster vaccine in this age group for several months.  ACIP has not yet voted on a 
recommendation for use of zoster vaccine among persons 50 through 59 years of age, although they 
may do so at their June 2011 meeting.  However, it is not necessary for clinicians to delay use of zoster 
vaccine in persons 50 through 59 years of age because of the absence of an ACIP recommendation. 
Zoster is licensed by the FDA for this age group so clinicians can administer the vaccine accordingly.  It 
should be noted that some insurance plans may not include zoster vaccine for 50-59 year olds as a 
covered benefit in the absence of an ACIP recommendation. 
 
Vaccine Information Statements (VISs) generally reflect ACIP recommendations for use of a vaccine 
rather than FDA licensure.  The current VIS for zoster vaccine does not reflect the new FDA-approved 
age group.  If and when ACIP votes to include 50-59 year olds in its recommendation for zoster vaccine 
the VIS will be revised accordingly. 
 
Updated Recommendations for Use of Meningococcal Conjugate Vaccines  
  
The Advisory Committee on Immunization Practices (ACIP) provided “Updated Recommendations 
for use of Meningococcal Conjugate Vaccines” in a Morbidity and Mortality Weekly Report (MMWR) 
dated January 28, 2011 / 60(03);72-76:  The report included new recommendations: 
 
Routine adolescent vaccination  
Administer vaccine to adolescents, preferably at 11 or 12 years, with a booster dose at 16 years of 
age.  For adolescents who receive the first dose at 13 through 15 years of age, a one-time booster 
dose should be administered, preferably at age 16 through 18 years.  Persons who receive their first 
dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose. 
 
College students 
Administer 1 dose of MCV4 to unvaccinated incoming college students ages 19 through 21 years, 
and consider vaccinating currently enrolled unvaccinated college students in this age group.  Give a 
booster dose of MCV4 to students younger than age 22 who are about to enter college if they 
received their most recent dose more than 5 years earlier, and consider giving booster doses to 
currently enrolled students who meet these criteria. 
 
High risk patients 
Administer a 2 dose primary series 2 months apart for persons 2 through 55 years of age with 
persistent complement component deficiency (e.g., C5-C9, properdin, factor H, or Factor D), 
functional or anatomic asplenia and for persons with human immunodeficiency (HIV) infection. 
 
The full report is available on the MMWR website. 
 
 
  
                                         
 
1. If the person is HIV-positive, give 2 doses, 2 months apart. 
2. The minimum interval between doses of MCV4 is 8 weeks. 
3. If the person received a 1-dose primary series, give booster at the earliest opportunity, 
then boost every 5 years. 
4. If younger than age 7 years, give booster dose after 3 years. 
5. A booster dose is recommended if the person remains at increased risk. 
 
Note: Children ages 2 through 10 years and adults ages 19 years and older without any of the risk 
factors listed above are not recommended for routine vaccination against meningococcal disease. If an 
adult patient requests vaccination against meningococcal disease, ACIP states that you can vaccinate 
them.  
 
Risk Group 
 
Primary Series If and when to give booster 
 
Persons ages 11 through 18 
years 
 
 
Give 1 dose of MCV4, 
preferably at age 11 or 12 
years1
 
 
Give booster at age 16 years if primary 
dose given at 12 years or younger 
 
Give booster at ages 16 through 18 years 
if primary dose given at 13 years through 
15 years2
 
 
Persons ages 19 through 21 
years who will be attending 
college 
 
Give 1 dose of MCV4, if 
previously unvaccinated.1 
 
Give booster dose if previous dose given 
at younger than 16 years 
 
Persons age 19 through 21 
years who are attending 
college 
 
May give 1 dose of MCV4, 
if previously unvaccinated.1 
 
May give booster dose if previous dose 
given at age younger than 16 years 
 
Persons with persistent complement component defiency (including C5-C9, properdin, factor H, 
factor D), or functional  or anatomic asplenia 
 
 
-for ages 2 though 55 years 
 
Give 2 doses of MCV4, 
 2 months apart 
 
Boost every 5 years with MCV43
 
 
-for age 56 years and older 
 
 
Give 1 dose of MPSV 
 
Boost every 5 years with MPSV  
 
Persons with prolonged increased risk for exposure (e.g., microbiologists routinely working with 
Neisseria meningitidis and travelers to or residents of countires where meningococcal disease is 
hyperendemic or epidemic) 
 
 
-for ages 2 through 55 years 
 
 
Give 1 dose of MCV41 
 
Boost every 5 years with MCV44,5 
 
-for age 56 years or older 
 
Give 1 dose of MPSV 
 
Boost every 5 years with MPSV5 
Summary of meningococcal vaccination recommendations, by risk group 
 2010 Immunization Annual Report 
 
The Immunization Program has released the 2010 Immunization Annual Report, which provides 
a summary of the activities and achievements of the Immunization Program and Iowa health 
care providers during the 2010 calendar year.  The report includes sections on Funding, Special 
Projects, Immunization Registry Information System (IRIS), Vaccines for Children Program 
(VFC), Perinatal Hepatitis B, and Immunization Assessments. The report serves as an 
informational resource for stakeholders, local partners, policy makers and the general public.  
 
Click here to view the full report.  
 
 
 
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria 
Toxoid and Acellular Pertussis (Tdap) Vaccine  
 
In response to an increased incidence of pertussis in the U.S., in October 2010, the ACIP voted 
on the following new recommendations for the use of Tdap vaccine:  
 
• Adults age 65 years and older  
o Those who have or anticipate having close contact with an infant less than 12 months 
of age should receive a single dose of Tdap. 
o Other adults 65 years of age and older may be given a single dose of Tdap. 
 
• Tdap is indicated for a single booster dose at 11 or 12 years of age if the childhood 
DTP/DTaP vaccination series has been completed. 
 
• Tdap should be given to persons 7-10 years of age and older who have received fewer 
than 5 doses of DTP/DTaP or 4 doses of DTP/DTaP if the fourth dose was administered 
at age 4 years or older; or have never been vaccinated against tetanus, diphtheria, or 
pertussis. 
 
• Adolescents and adults who have not received Tdap should receive a single dose of 
Tdap in place of a single Td booster dose. 
 
• Tdap is recommended only for a single dose across all age groups. 
 
• Tdap can be administered regardless of the interval since the last tetanus or diphtheria 
containing vaccine. 
 
The full report is available on the MMWR website. 
 
 
 
Question Corner 
Q.  Sometimes the Advisory Committee on Immunization Practices (ACIP) recommendations 
are different from the FDA-approved package insert indications. Which do I follow? 
 
A.  The Advisory Committee on Immunization Practices (ACIP) routinely makes immunization 
recommendations which represent the standard of care for vaccination practice in the United 
States.  Recommendations from the ACIP and vaccine manufacturer package inserts are usually in 
agreement.  However, the ACIP may make additional recommendations to add flexibility to its 
recommendations or use of expert opinion such as the American Academy of Pediatrics (AAP) or 
other medical organization.  The ACIP includes representation from many organizations including 
the American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP).  
Published recommendations from these groups should be considered equally as authoritative as 
those on the vaccine manufacturer package insert.  In general, to determine recommendations for 
use, one should follow the recommendations of ACIP rather than the information in the package 
insert.  ACIP recommendations represent the standard of care for vaccination practice in the 
United States.  
 
Q.  A 19-year-old student who received 1 dose of MCV4 at age 12 years will be attending a 
community college this fall. Does she need a booster dose of MCV4?  
 
 A.  Yes. Adults ages 19 through 21 years who plan to attend college, and who received the 
previous dose of MCV4 before 16 years of age, need a booster dose.  These individuals no longer 
need to be living in on-campus housing to qualify in a risk group for meningococcal vaccination. 
 
Q.  An 8 year-old child with a history of 3 DTaP all given before 12 months of age-which 
tetanus product should I give? 
 
 A.  Give the child one dose of Tdap to complete the series.  Children ages 7-10 years who 
are not fully immunized against pertussis (i.e., did not complete a series of pertussis-containing 
vaccine before their 7th birthday) should receive a one-time dose of Tdap.  (Definition of fully 
immunized for pertussis-received 5 doses of DTP/DTaP or 4 doses of DTP/DTaP if the fourth dose 
was administered at age 4 years or older) 
 
Q.  In cleaning the vaccine vial stopper, is it okay to use a non-sterile cotton ball or do we 
need to use a pre-packaged sterile alcohol prep pad? 
 
  A. Using a pre-packaged sterile alcohol prep pad is recommended to maintain aseptic 
technique.  Not only are cotton balls not sterile, but neither is a bottle of sterile alcohol, once it's 
opened. 
 
 
 
 
 
 
 VFC Spotlight 
VFC Eligibility Criteria 
 
Health care providers enrolled in the Vaccines for Children Program may only administer VFC 
vaccine to VFC Program eligible patients.  Children birth through 18 years of age who meet the 
following criteria may receive VFC vaccine: 
 
๐  Child is enrolled in Medicaid 
Children enrolled in the following Medicaid Programs are eligible for the VFC 
Program:  Medipass Gatekeeper Program, IA Cares, and Medicaid as 
secondary health coverage.  Individuals who have a primary health insurance 
company and Medicaid as secondary coverage are eligible for the VFC 
Program and should be immunized using VFC vaccine. 
๐  Child has no health insurance coverage 
๐  Child is American Indian or Alaskan Native 
๐  Child is underinsured - served by a FQHC, RHC or LPHA 
Underinsured children includes those who have health insurance but the 
benefit plan does not include immunizations, covers only select vaccines, or 
caps the vaccine cost at an established limit.  Underinsured children are 
eligible to receive VFC vaccine only if they are served by a Federally 
Qualified Health Center, Rural Health Clinic or local public health 
agency. 
 
Children whose health insurance covers the cost of vaccinations are NOT eligible for VFC 
Program benefits even when a claim for the cost of the vaccine and its administration would be 
denied if submitted to the insurance carrier for payment because the plan’s deductible (high 
deductible plan) had not been met. 
 
Some insurance plans may cover all ACIP-recommended childhood vaccines but exclude 
certain combination vaccines or certain products.  A child with this type of coverage would be 
considered insured and NOT eligible for VFC because all recommended vaccines are covered.  
Some insurance plans may cover a portion of the cost of the vaccine, even though it may be 
only a small portion of the cost of the vaccine, this child is considered insured for the purposes 
of the VFC Program. 
 
Children enrolled in hawk-i are not eligible under the VFC Program since the hawk-i Program 
is a full coverage insurance plan.  Children enrolled in hawk-i must be vaccinated with privately 
purchased vaccine. 
 
Screening to determine a child’s eligibility for the VFC Program must take place with each 
immunization visit.  Verification of parent/guardian/individual responses is not required.  For 
each child enrolled, a Patient Eligibility Screening Record or equivalent must be completed and 
kept on file for at least three years regardless of VFC eligibility. 
 
  
 
Vaccines 
 
 The Iowa VFC Program offers each vaccine listed on the CDC vaccine contract.  Due to 
constraints and limitations imposed by CDC, McKesson, or the vaccine manufacturers, 
particular brands of vaccine may not be available each time a clinic orders.  If a vaccine is 
unavailable, the IRIS order form will be updated to show available products.  VFC Providers 
should make every effort to use all of a vaccine before switching to another product.  When 
placing vaccine orders it is important to review your vaccine inventory to identify all vaccines 
needed.  To prevent vaccine wastage, it is important to monitor your supply of single antigen 
vaccines and reduce inventory to appropriate levels prior to implementing a new combination 
vaccine.  Providers may be held liable for vaccine cost as a result of excessive vaccine 
wastage.  
 
Vaccine Borrowing 
 
 Vaccine borrowing should be the exception and not the rule.  All providers are expected 
to maintain adequate inventories of vaccine to administer to privately insured and VFC-eligible 
children.  Borrowing of vaccine must be due to an unforeseen delay or circumstance 
surrounding vaccine that was ordered.  Borrowing can only occur after receiving prior approval 
from the VFC Program by calling 800-831-6923, ext 4.  Employee training should be conducted 
to ensure that all staff understands the difference between VFC and privately purchased 
inventory and the potential issues excessive borrowing can cause such as accountability and 
inventory issues. 
 
 
                
         
 
 
REGISTRATION IS NOW OPEN! 
The 2011 Iowa Immunization Conference will be on June 8 & 9, 2011. 
Click on the following link to register.  
2011 Iowa Immunization Conference Registration 
 
The Bureau of Immunization & TB has a new web page!  
 
Conferences & Resources 
